Julie Eastland

Julie Eastland is a seasoned strategic and financial executive with more than 25 years of experience in the public and private biotechnology industry. She previously served as Chief Operating Officer and Chief Financial Officer of ReCode Therapeutics, a private genetic medicines company developing therapeutics using its proprietary lipid nanoparticle delivery technology to target organs and tissues beyond the liver. Prior to ReCode, she served as Chief Financial Officer and Chief Business Officer of Rainier Therapeutics, a private biopharmaceutical company focused on FGFR3 bladder cancer. Prior to Rainier, she served as Chief Financial Officer and Chief Business Officer of Cascadian Therapeutics, a publicly-traded oncology company that was acquired by Seattle Genetics in 2018. While at Cascadian, she was instrumental in the negotiation and sale of the company, primarily for its product tucatinib, a HER2 targeted breast cancer therapy now marketed as Tukysa®. Prior to Cascadian, she served as Chief Financial Officer and Vice President of Finance and Operations of VLST Corporation, a privately-held biotechnology company, and held various financial and strategic management positions at publicly traded biotechnology companies including Dendreon and Amgen. Ms. Eastland received an M.B.A. from Edinburgh University Management School and a B.S. in finance from Colorado State University. In addition to serving on the board at Harpoon Therapeutics, she serves on the board of Dynavax Technologies (Nasdaq: DVAX).
Speaking In
3:30 PM - 4:30 PM
Monday, June 5
In today’s turbulent market backdrop, both life science companies and investors are required to…